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Abstract
Background: This study estimated the prevalence of curable sexually transmitted and reproductive tract infections
(STIs/RTIs) among pregnant women attending antenatal care (ANC) in rural Zambia, evaluated the effectiveness of
syndromic management of STIs/RTIs versus reference-standard laboratory diagnoses, and identified determinants of
curable STIs/RTIs during pregnancy.
Methods: A total of 1086 pregnant women were enrolled at ANC booking, socio-demographic information and
biological samples were collected, and the provision of syndromic management based care was documented. The
Piot-Fransen model was used to evaluate the effectiveness of syndromic management versus etiological testing,
and univariate and multivariate logistic regression analyses were used to identify determinants of STIs/RTIs.
Results: Participants had a mean age of 25.6 years and a mean gestational age of 22.0 weeks. Of 1084 women, 700
had at least one STI/RTI (64.6%; 95% confidence interval [CI], 61.7, 67.4). Only 10.2% of infected women received any
treatment for a curable STI/RTI (excluding syphilis). Treatment was given to 0 of 56 women with chlamydia
(prevalence 5.2%; 95% CI, 4.0, 6.6), 14.7% of participants with gonorrhoea (prevalence 3.1%; 95% CI, 2.2, 4.4), 7.8% of
trichomoniasis positives (prevalence 24.8%; 95% CI, 22.3, 27.5) and 7.5% of women with bacterial vaginosis
(prevalence 48.7%; 95% CI, 45.2, 51.2). An estimated 7.1% (95% CI, 5.6, 8.7) of participants had syphilis and received
treatment. Women < 20 years old were more likely (adjusted odds ratio [aOR] = 5.01; 95% CI: 1.23, 19.44) to have
gonorrhoea compared to women ≥30. The odds of trichomoniasis infection were highest among primigravidae
(aOR = 2.40; 95% CI: 1.69, 3.40), decreasing with each subsequent pregnancy. Women 20 to 29 years old were more
likely to be diagnosed with bacterial vaginosis compared to women ≥30 (aOR = 1.58; 95% CI: 1.19, 2.10). Women
aged 20 to 29 and ≥ 30 years had higher odds of infection with syphilis, aOR = 3.96; 95% CI: 1.40, 11.20 and aOR =
3.29; 95% CI: 1.11, 9.74 respectively, compared to women under 20.
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Conclusions: Curable STIs/RTIs were common and the majority of cases were undetected and untreated.
Alternative approaches are urgently needed in the ANC setting in rural Zambia.
Keywords: Syndromic management, Sexually transmitted infections, Reproductive tract infections, Bacterial
vaginosis, Prevalence, Risk factors, Sub-Saharan Africa
Background
Curable sexually transmitted and reproductive tract infec-
tions (STIs/RTIs) – chlamydia, gonorrhoea, trichomonia-
sis, bacterial vaginosis, and syphilis – are important causes
of adverse pregnancy outcomes. Chlamydia (Chlamydia
trachomatis) increases the odds of preterm birth four-fold
[1], and more than doubles the chances of experiencing
premature rupture of the membranes [1], delivering a
newborn who is low birthweight [1] or small-for-
gestational age [2]. Gonorrhoea (Neisseria gonorrhoeae) is
associated with a three-fold increase in preterm birth [3].
Trichomoniasis (Trichomonas vaginalis), the most preva-
lent curable STI in the world, increases the odds of pre-
term delivery 1.5 times [4]. Bacterial vaginosis, the most
common urogenital disorder in the world among women
of reproductive age, increases the odds of preterm delivery
two-fold [4]. Bacterial vaginosis and trichomoniasis both
double the odds of delivering a low birthweight child [4].
Syphilis (Treponema pallidum) is associated with four of
every ten spontaneous abortions [5, 6], and one-quarter of
stillbirths [7]. Pregnant women who have curable STIs are
at elevated risk of HIV acquisition during pregnancy [8,
9], whereas HIV-infected pregnant women who have cur-
able STIs at delivery are at increased risk of giving birth to
an HIV-infected infant [10].
To reduce the burden of congenital syphilis, the World
Health Organization (WHO) recommends universal
screening of pregnant women at antenatal care (ANC)
booking and the provision of 2.4MU benzathine penicil-
lin G to individuals who test positive. For the diagnosis
of urethral discharge and genital ulcer disease that in-
clude chlamydia, gonorrhoea, trichomoniasis, and bac-
terial vaginosis, the WHO recommends the use of
diagnostic and treatment algorithms called syndromic
case management [11] in low-resource areas where la-
boratory facilities and trained staff are unavailable. Syn-
dromic management is based on the identification of
consistent groups of symptoms and easily recognized
signs and treatment that is effective against the majority
or most serious organisms responsible for producing a
syndrome. This approach can be effective for diagnosing
and treating men. However, curable STIs/RTIs are often
asymptomatic among women for whom the algorithms
fail to diagnose 70 to 80% of chlamydial and gonococcal
infections [12], and 60 to 70% of trichomoniasis and
bacterial vaginosis cases [13, 14].
The co-infection prevalence estimates of STI/RTI and
malaria infection among pregnant women in the Nchelenge
District of Zambia has been previously reported [15].
Nchelenge is a rural area with a population of approxi-
mately 173,680 [16] on the shores of Lake Mweru in the
Luapula Province. In this analysis the prevalence of curable
STIs/RTIs among pregnant women, effectiveness of the
syndromic case management for diagnosis of curable STIs/
RTIs compared to reference-standard laboratory assays,
and risk factors for having a curable STI/RTI during preg-
nancy are presented.
Methods
The main study involved an observational cohort of
women enrolled at first ANC visit and followed to deliv-
ery. Participants were enrolled (n = 1086) who were less
than 32 gestational weeks measured by ultra-sound dur-
ing their first ANC visit to Nchelenge and Kashikishi
health facilities from November 2013 to April 2014 [17].
Consistent with Zambian ANC policy, clinic staff
screened pregnant women and their partners for HIV
[18, 19]. Venous blood was collected from women for
syphilis testing by rapid plasma reagin (RPR) (Omega
Diagnostics Limited, Alva, Scotland, United Kingdom)
and RPR-positive women were treated with 2.4 MU of
benzathine penicillin G together with their partners ac-
cording to national norms [20]. Clinic staff recorded par-
ticipant socio-demographic information and obstetric
history during the first visit. As part of standard ANC,
clinic staff asked women at antenatal care visits if they
had experienced any symptoms associated with STIs/
RTIs prior to enrolment. If women responded in the af-
firmative, they were screened further and treated based
on syndromic management guidelines by the clinic staff.
Apart from routine care, clinic staff collected cervico-
vaginal swabs and stored them at the district hospital.
Samples were transported to the University Teaching
Hospital in Lusaka where molecular detection of the
presence of each organism of interest, C. trachomatis, N.
gonorrhoeae and T. vaginalis was conducted. Polymerase
chain reaction methods were used to identify species of
interest with positive and negative controls at the stages
of extraction, amplification and electrophoresis [21–23].
Bacterial vaginosis was diagnosed by microscopy using
gold standard Nugent criteria [24]. Results of these as-
says were communicated to participating clinics and
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study staff who traced positive cases to their homes and
encouraged women to seek treatment from the clinics at
no cost. Separately, to confirm syphilis positivity, Trepo-
nema pallidum haemagglutination assays were per-
formed (Chronolab Systems, Barcelona, Spain) on
samples that were RPR seropositive.
Data processing and analysis
Data were double-entered and cleaned in EpiData soft-
ware version 3.1 [25] and analysed with Stata IC 13 soft-
ware [26]. The prevalence of curable STIs/RTIs and 95%
CIs were estimated, and the Piot-Fransen model was ap-
plied to evaluate the effectiveness of syndromic case man-
agement versus etiological testing in the ANC setting. The
Piot-Fransen model has been previously used to identify
weaknesses in case management of STIs [27], malaria
[28], and tuberculosis [29]. The prevalence estimates were
stratified by HIV status and odds ratios (OR) were esti-
mated in univariate logistic regression models that con-
tained variables we considered a priori to be potential risk
factors. For each infection, risk factors were then assessed
in a multivariable model using a likelihood-ratio test. Risk
factors that were assessed included maternal age, gravidity,
marital status, years of schooling, number of life-time sex-
ual partners, self-reported STI/RTI related symptoms and
HIV status. The final model for each infection included
risk factors that demonstrated an effect in the adjusted
model at the 5% significance level and on the adjusted OR
estimates for individual STIs/RTIs. Models were also pro-
duced for having any STI/RTI.
Results
In total, 1086 women were recruited to the study, with
one withdrawing consent during the study. Background
characteristics of participants have been reported else-
where [15]. Briefly, women had a mean age of 25.6 years
(95% CI: 25.1, 25.9) and a mean gestational age of 22.0
weeks (95% CI: 21.7, 22.2); 55.3% (600 of 1085) had
some primary school education, and 80.6% (874 of 1085)
were married. The mean age of sexual debut was 17.2
years (range 10 to 28 years). Overall, 13.2% (95% CI:
11.3, 15.3) of women tested positive for HIV. Multigrav-
idae (99 of 658) had the highest prevalence of HIV,
15.0% (95% CI: 12.5, 18.0), followed by secundigravidae
(23 of 165) at 13.9% (95% CI: 9.4, 20.1%), and 8.0% (95%
CI: 5.3, 12.0%) among primigravidae (21 of 261), P-
value = 0.018.
Prevalence of individual STIs/RTIs
In total, samples from 1084 women were available for
analysis. However, three samples for bacterial vaginosis
and seven samples for syphilis were not evaluable.
Table 1 contains a complete summary of prevalence esti-
mates of STIs/RTIs for all women and those who were
HIV positive. Among women tested, 64.6% (95% CI,
61.7, 67.4) had at least one curable STI/RTI (700 of
1084). An estimated 5.2% (95% CI: 3.9, 6.7) of partici-
pants had chlamydia (56 of 1084) with no significant dif-
ference between women with HIV and those without.
Among the five curable STIs/RTIs investigated, gonor-
rhoea was the least prevalent (34 of 1084) at 3.1% (95%
CI: 2.2, 4.4). Gonorrhoea was more common among
HIV-infected women compared to those without HIV.
One-quarter of women (269 of 1084) had trichomonia-
sis, 24.8% (95% CI: 22.3, 27.5), and there was no differ-
ence in the prevalence between HIV-infected and HIV-
uninfected women. Bacterial vaginosis was diagnosed
among 48.2% (95% CI: 45.2, 51.2) of women (521 of
1081). Participants with HIV were more likely to have
bacterial vaginosis, than HIV-uninfected women. An es-
timated 7.1% (95% CI: 5.6, 8.7) of participants had syph-
ilis (76 of 1077) and the proportion was more than
double among women with HIV.
Effectiveness of syndromic case management
Overall, 12.4% of women self-reported symptoms associ-
ated with STIs/RTIs at the time of recruitment and
18.0% reported experiencing symptoms during the preg-
nancy duration including at recruitment. Of women who
had at least one curable STI/RTI, 86.0%, (602 of 700)
were asymptomatic at recruitment. Among women with
chlamydia, 83.9% (47 of 56) were asymptomatic, as were
76.5% (26 of 34) of gonorrhoea cases, 84.4% (227 of 269)
of trichomoniasis cases, and 86.0% (448 of 521) of
women diagnosed with bacterial vaginosis. Figure 1 illus-
trates the Piot-Fransen model and quantifies the number
as well as proportion of women tested for each STI/RTI,
the proportion of symptomatic versus asymptomatic in-
fections identified, and the number of women with STIs/
RTIs who received treatment. Overall, only 10.2% (69 of
680) of curable STI/RTI cases, excluding syphilis, re-
ceived treatment. Of the 98 symptomatic women, 43
cases were given treatment. Not one chlamydial infec-
tion of 56 was treated. In contrast, treatment was pro-
vided to 14.7% of women with gonococcal infections (5
of 34), 7.8% of trichomoniasis cases (21 of 269), and
7.5% of women with bacterial vaginosis (39 of 521).
The proportion of women experiencing symptomatic
STIs/RTIs at recruitment was higher among HIV-positive
women, 19.6%, (28 of 143) compared to HIV-negative
women, 11.3%, (106 of 941), P-value = 0.005. More HIV-
positive participants received treatment than HIV-
negative women, but this was not statistically significant,
16.4% versus 10.5%, respectively, P-value = 0.076.
Risk factors for STIs/RTIs
Among the five curable STIs/RTIs, only chlamydia had
no particular risk factor that was identified to be
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associated with infection. HIV infection was associated
with having gonorrhoea, (aOR = 2.80; 95% CI: 1.25,
6.26), adjusted for age; bacterial vaginosis (aOR = 2.41;
95% CI: 1.66, 3.51), adjusted for age; syphilis infection
(aOR = 2.56; 95% CI: 1.48, 4.41) adjusted for age; the
number of life-time sexual partners and having any STI/
RTI (aOR = 2.10; 95% CI: 1.39, 3.19), adjusted for age.
There was an inverse association between age and
gonorrhoea. Compared to women 30 years and older, the
odds of gonococcal infection were five-times greater
among pregnant women under 20 years of age (aOR =
5.01; 95% CI: 1.29,19.44), and four-times higher among
participants between 20 and 29 (aOR = 4.27; 95% CI: 1.32,
14.94) after adjusting for HIV infection. A similar relation-
ship between gravidity and trichomoniasis was identified.
In contrast to multigravidae (4th), primigravidae had the
highest odds of trichomonas infection (aOR = 2.40; 95%
CI: 1.69, 3.40), followed by secundigravidae (aOR = 2.06;
95% CI: 1.37, 3.10), and then multigravidae (3rd) (aOR =
1.58; 95% CI: 1.05, 2.39) after adjusting for self-reported
STI/RTI symptoms. Women 20 to 29 years of age had a
58% greater chance of experiencing bacterial vaginosis
(aOR = 1.58; 95% CI: 1.19, 2.10) compared to women 30
years of age and older adjusted for HIV infection. Women
aged below 20 years had higher odds of being diagnosed
with bacterial vaginosis compared to women aged 30 years
and older, but this association was not statistically signifi-
cant. However, compared to women aged 30 years and
above, women aged 20–29 had increased odds of infection
with bacterial vaginosis, aOR = 1.58; 95% CI: 1.19, 2.10
after adjusting for HIV status. Women younger than 20
years of age, and those between 20 to 29 years, had higher
Table 1 Prevalence of curable STIs/RTIs among all pregnant women (N = 1084) at antenatal care booking and by HIV status
Curable STI/RTI (n) Cases among all women Cases among HIV-infected women*
% positive 95% CI % positive 95% CI P-value¥
Chlamydia
Positive 56 (5.2) 3.9, 6.7 10 (7.0) 3.8, 12.6 0.291
Paucigravidae (426) 28 (6.6) 4.6, 9.4 5 (11.4) 4.7, 24.5 0.236
Multigravidae (658) 28 (4.3) 3.0, 6.1 5 (5.1) 2.1, 11.7 0.718
Gonorrhoea
Positive 34 (3.1) 2.2, 4.4 9 (6.3) 3.3, 11.7 0.020
Paucigravidae (426 17 (4.0) 2.5,6.3 3 (6.8) 2.2, 19.5 0.227
Multigravidae (658) 17 (2.6) 1.6, 4.1 6 (6.1) 2.7, 12.9 0.059
Trichomoniasis
Positive 269 (24.8) 22.3, 27.5 34 (23.8) 17.5, 31.5 0.752
Paucigravidae (426) 139 (32.6) 28.3, 37.2 13 (29.5) 17.8, 44.8 0.676
Multigravidae (658) 130 (19.8) 16.9, 23.0 21 (21.2) 14.2, 30.5 0.745
Bacterial vaginosis
Positive 521 (48.2) 45.2, 51.2 95 (66.4) 58.3, 73.7 < 0.001
Paucigravidae (423) 212 (50.1) 45.4, 54.9 31 (70.5) 55.2, 82.2, 0.001
Multigravidae (658) 309 (47.0) 43.2, 50.7 64 (64.6) 55.6, 73.5 0.001
Syphilis
Positive 76 (7.1) 5.6, 8.7 22 (15.8) 10.6, 23.0 < 0.001
Paucigravidae (425) 28 (6.6) 4.5, 9.3 11 (25.6) 14.6, 40.9 < 0.001
Multigravidae (652) 48 (7.4) 5.6, 9.6 11 (11.5) 6.4, 19.7 0.160
Any STI/RTI
Positive 700 (64.6) 61.7, 67.4 110 (76.9) 69.2, 83.2 0.001
Paucigravidae (426) 294 (69.0) 64.4, 73.2 38 (86.4) 72.5, 93.8 0.016
Multigravidae (658) 406 (61.7) 57.9, 65.3 72 (72.7) 63.0, 80.7 0.034
HIV Human Immunodeficiency Virus
Samples that were processed for the detection of each infection were as follow; detection of chlamydia, gonorrhoea and trichomoniasis 1084 samples instead of
1085 were processed; detection of syphilis 1077 instead of 1085 and for detection of bacterial vaginosis 1081 instead of 1085 samples were processed due to
missing samples
The HIV status of one participant was not determined and, therefore, was excluded from this analysis
*A total of 143 participants were HIV positive, 44 paucigravidae and 99 multigravidae
¥ P-value obtained from the two-sample test of proportions which was used to test the difference in prevalence of each infection among HIV positive and HIV
negative women
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odds of having any STI/RTI compared to pregnant coun-
terparts 30 years and above, aOR = 1.70; 95% CI: 1.16, 2.78
and aOR = 1.58; 95% CI: 1.18, 2.11, respectively, after
adjusting for HIV infection.
There was a statistically significant association between
syphilis and age. Compared to participants under the age
of 20, the odds of a syphilis infection were four-times
higher among women from 20 to 29, (aOR = 3.96;95% CI:
1.40, 11.20), and three-times higher among women 30 and
older, (aOR = 3.29; 95% CI: 1.11, 9.74) adjusted for HIV
infection and number of life-time sexual partners. The
odds of having syphilis nearly doubled among women
who had three or more life-time partners versus those
who had just one or two partners (aOR = 1.82; 95% CI:
1.12, 2.98) adjusted for HIV-infection and age. Table 2
shows a summary of the crude and adjusted ORs of risk
factors for each STI/RTI. Supplementary Tables 1, 2, 3, 4,
5, 6 contain complete results for the risk-factor models for
individual infections and composite STIs/RTIs.
Discussion
The prevalence of curable STIs among pregnant women
is substantial throughout low- and middle-income
countries [30]. Nearly two-thirds of all pregnant women
in our cohort had a curable STI/RTI at antenatal booking.
These findings are consistent with the pooled prevalence
estimates of curable STIs/RTIs among pregnant women
attending ANC services across East and Southern Africa
[31]. The distribution of infection within this study group
may have been affected by the large proportion of multi-
gravidae, 60.7% (659 of 1085). This age structure may have
made it more difficult to detect young age as a risk factor
for chlamydia as reported elsewhere among pregnant [32]
and non-pregnant women [33]. HIV-infected pregnant
women aged less than 25 years were found to have higher
odds of infection with chlamydia, gonorrhoea or tricho-
moniasis [34]. However, other studies have reported fail-
ure to identify any particular risk factors for chlamydial
infection [35, 36] as in the current study. Risk factors asso-
ciated with gonorrhoea were age related, i.e. being youn-
ger than age 30, similar to findings from Botswana and
may suggest circulation of Neisseria gonorrhoea in youn-
ger networks of sexually active individuals [37].
Bacterial vaginosis was associated with HIV infection, a
common observation among mothers with HIV [38, 39].
Syphilis prevalence was alarmingly high in our study, 7.1%
Fig. 1 Effectiveness of syndromic management of curable STIs/RTIs among pregnant women in the Nchelenge District, Zambia. * Asymptomatic
versus symptomatic status was unavailable from one woman with chlamydia and bacterial vaginosis; †4 were asymptomatic; ‡9 were
asymptomatic; § 28 were asymptomatic
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Table 2 Risk factors associated with gonorrhoea, trichomoniasis, syphilis, bacterial vaginosis and any sexually transmitted and
reproductive tract infection among pregnant women at antenatal care booking






< 20 3.9 96.1 204 4.14 (1.08, 15.78) 5.01 (1.29, 19.44)
20–29 4.0 96.0 573 4.24 (1.26, 14.22) 4.27 (1.32, 14.94)
30+ 1.0 99.0 307 Ref Ref
HIV status
Negative 2.7 97.3 940 Ref Ref
Positive 6.3 93.7 143 2.46 (1.12, 5.38) 2.80 (1.25, 6.26)
Trichomoniasis
Pregnancy number
Primigravidae 34.1 65.9 261 2.39 (1.69, 3.38) 2.40 (1.69, 3.40)
Secundigravidae 30.3 69.7 165 2.01 (1.34, 3.02) 2.06 (1.37, 3.10)
Multigravidae (3rd) 25.0 75.0 180 1.54 (1.02, 2.32) 1.58 (1.05, 2.39)
Multigravidae (4th) 17.8 82.2 478 Ref Ref
Self-reported STI/RTI symptoms during current pregnancy
No 23.4 76.6 880 Ref Ref
Yes 31.8 68.2 198 1.53 (1.09, 2.14) 1.56 (1.11, 2.20)
Bacterial vaginosis
Age group
< 20 44.6 55.4 202 1.10 (0.76, 1.57) 1.23 (0.85, 1.77)
20–29 52.7 47.3 571 1.53 (1.15, 2.02) 1.58 (1.19, 2.10)
30+ 42.2 57.8 308 Ref Ref
HIV status
Negative 45.5 54.5 937 Ref NA
Positive 66.4 33.6 143 2.37 (1.64, 3.44) 2.41 (1.66, 3.51)
Syphilis
Age group
< 20 2.0 98.0 204 Ref Ref
20–29 8.6 91.4 568 4.72 (1.68, 13.25) 3.96 (1.40, 11.20)
30+ 7.5 92.5 305 4.08 (1.39, 11.97) 3.29(1.11, 9.74)
Number of lifetime sexual partners
≤ 2 5.7 94.3 792 Ref Ref
≥ 3 11.3 88.7 275 2.11 (1.31, 3.41) 1.82 (1.12, 2.98)
HIV status
Negative 5.8 94.2 938 Ref Ref
Positive 15.8 84.2 139 3.08 (1.81, 5.24) 2.56 (1.48, 4.41)
Any STI/RTI
Age group
< 20 67.7 32.4 204 1.56 (1.07, 2.25) 1.70 (1.16, 2.78)
20–29 67.4 32.6 573 1.54 (1.15, 2.04) 1.58 (1.18, 2.11)
30+ 57.3 42.6 307 Ref Ref
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overall. At the population level, syphilis infection tends to
be more common among older women and, therefore,
having a large proportion of multigravidae in our co-
hort may have skewed the prevalence of maternal
syphilis upward. The reason for this may be related
to the natural course of the disease. After initial ul-
cers of primary infection heal, syphilis often becomes
asymptomatic, persisting untreated for years. In our
cohort study, primi- and secundigravidae represented
36.8% of syphilis infections (28 of 76), whereas 63.2%
(48 of 76) were multigravidae. Even given the age
structure of our cohort, women of Nchelenge District
may experience a disproportionate burden of maternal
syphilis. In 2012, an estimated 2.4% of pregnant
women in Zambia had syphilis, increasing marginally
to 2.5% by 2016 [40]. In sub-Saharan Africa, 1.6% of
pregnant women had syphilis in 2012, lowering
slightly to 1.5% in 2016 [40].
Identification of risk factors for infection can play a
role in the development of a profile for high risk groups
for the purpose of directing the limited resources to
where they are needed most. Development of a tool to
identify women at high risk of infection can allow for ei-
ther provision of presumptive treatment to high risk
pregnant women or screening high risk pregnant women
at ANC visits for STI/RTIs and provision of treatment
for positive cases.
Public health response
Syndromic management of curable STIs/RTIs clearly
demonstrated limited utility given that only 10.2% of
women with infections, apart from syphilis, received any
treatment. Of the women with symptomatic curable
STI/RTI, 43.9% received treatment according to national
norms. Women were asked whether they were experien-
cing anything from a list of STI/RTI related symptoms.
This created the basis of the classification of women to
the symptomatic and asymptomatic group. However, re-
sponses to individual symptoms were not recorded. Con-
sequently, it is not possible to draw conclusions about
the appropriateness of the care that was administered.
Even under optimal circumstances, syndromic man-
agement is unlikely to perform much better given that
86% of the curable STIs/RTIs were asymptomatic in this
setting. High prevalence of untreated STIs/RTIs means
high prevalence of avoidable adverse pregnancy out-
comes. The shortcomings of syndromic management in
pregnancy have been documented [10, 32, 41], but pub-
lic health responses have been lacking. Given that point
of care (POC) tests for C. trachomatis, N. gonorrhoea
and T. vaginalis are available [42], there is an urgent
need to evaluate them in the antenatal setting as an al-
ternative to syndromic management, particularly where
risk factors may be used to guide testing [43]. Studies in-
dicate that integration of POC diagnostic STI screening
into first ANC among pregnant HIV-infected women is
feasible [44, 45] and acceptable [44] although this has
not been evaluated in mixed populations of HIV-
infected and HIV-uninfected pregnant women. Due to
lack of infrastructure and trained laboratory staff, con-
ventional testing for STIs/RTIs is often unavailable in re-
source poor settings such as this study site. Until the
necessary capacity is present, POC tests represent an im-
portant alternative for diagnosing chlamydia, gonorrhoea
and trichomoniasis in such areas.
Chlamydia and gonorrhoea
Chlamydia and gonorrhoea POC tests merit investiga-
tion. Given that each test represents a fixed-cost, it
would be useful to explore whether the use of POC tests
among women who are at risk of chlamydia and gonor-
rhoea might be able to achieve similar reductions in
adverse pregnancy outcomes attributable to these infec-
tions as universal screening and case management. In
this study group, no specific risk factors for women who
had chlamydial infection were identified. Consequently,
universal POC testing should be considered in this set-
ting first and foremost until a more targeted approach
can be established based on risk profiles for chlamydial
infection in this population. In the case of gonorrhoea,
universal POC testing should be evaluated against an ap-
proach of targeted screening for pregnant women under
30 years of age, or those with HIV infection.
It would be important to establish differential diagno-
ses between chlamydia and gonorrhoea due of treatment
implications, even though just three of 90 (3.3%)
Table 2 Risk factors associated with gonorrhoea, trichomoniasis, syphilis, bacterial vaginosis and any sexually transmitted and
reproductive tract infection among pregnant women at antenatal care booking (Continued)





Negative 62.8 37.2 940 Ref Ref
Positive 76.9 23.3 143 1.98 (1.31, 2.98) 2.10 (1.39, 3.19)
¥For bacterial vaginosis the number included the intermediate and normal subgroups
*Adjusted for all the variables in the left-hand column of Supplemental Tables 1, 2, 3, 4, 5; The multivariate model only included factors that were significant at
P < 0.05 using the likelihood ratio test. Ref = Reference group with the odds ratio set at 1
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pregnant women in Nchelenge were co-infected. The
WHO recommends treating chlamydia during preg-
nancy with a one-time 1 g dose of azithromycin. The
same dose, however, may also hasten the emergence of
untreatable gonorrhoea among women with co-infection
[46]. Gonorrhoea in pregnancy, per WHO guidelines,
should be treated with either ceftriaxone 250 mg by
intramuscular injection plus azithromycin 1 g orally, or
cefixime 400 mg orally plus azithromycin 1 g orally [47].
If differential diagnoses cannot be established, there may
be reason to provide a curative dose for gonorrhoea
which would clear co-infection and reduce opportunity
for gonococcus to be exposed to azithromycin mono-
therapy. Screening and treatment of infected partners
needs to be provided with such an approach. There is a
convenient dual-cassette POC test available that can de-
tect chlamydia and gonorrhoea with one biological sam-
ple [42], but cost is significant barrier to routine use.
Trichomoniasis and bacterial vaginosis
Universal screening and treatment for trichomoniasis
and bacterial vaginosis would be an important improve-
ment over syndromic management, particularly given
how prevalent both are in this setting. Pregnant women
diagnosed with either trichomoniasis or bacterial vagin-
osis could be given a single 2-g dose of metronidazole as
recommended by the WHO [48]. Another option might
be simply to provide metronidazole to all women at
ANC booking. These two approaches need to be evalu-
ated for their protective effect against adverse pregnancy
outcomes and the cost per adverse outcome averted.
Part of the comparison should include partner screening
for trichomoniasis and appropriate case management.
Syphilis
Efforts must be redoubled to ensure syphilis POC tests
are available to all women at ANC booking and that 2.4
MU benzathine penicillin G is in stock to treat cases. As
with other curable STIs, partner screening and treatment
is needed to prevent re-exposure from infected partners.
In the case of syphilis, this is particularly important. Ver-
tical transmission of syphilis has been reported in all
stages and sub-stages of infection. However, congenital
infection is more likely to occur and be most severe
among pregnant women with first-stage syphilis (which
includes primary, secondary and early-latent infections
up to 2 years following exposure) than second-stage
syphilis. Thus, if a woman is at risk of reinfection or
resident in communities where syphilis prevalence is
high, monthly quantitative titres are suggested from the
third trimester to delivery [49].
This observational cross-sectional study is not without
limitations. The prevalence and risk factors for curable
STIs/RTIs we observed may not reflect all pregnant
women in rural Zambia if there were differences be-
tween women who seek antenatal care and those who
do not. Any difference, however, would not likely change
the results substantially because ANC attendance (mini-
mum one visit) in this part of Zambia was 94.6% [50],
and the refusal rate in the study among eligible women
was less than 1%. Another study limitation relates to the
type of information required for comprehensive risk fac-
tor analyses. Some women, for example, may have been
reluctant to provide accurate responses to questions re-
lated to sexual behaviour and practices. This is particu-
larly the case given the increasing participation of male
partners at the first ANC visit. In the current study,
women were asked whether they were experiencing any
STI/RTI symptoms. Responses, however, were not dif-
ferentiated. Therefore, it was only possible to determine
whether treatment was given to symptomatic women,
but not if the treatment was appropriate. Another limita-
tion is that information on alcohol or substance abuse
was not collected. Finally, the study was under powered
to detect risk factors with ORs < 1.5. Regardless, results
from this observational cross-sectional study clearly
show that the status quo is unacceptable and that new
interventions are warranted. STI vaccines remains under
development. Until they are ready to deploy, clinical tri-
als are urgently needed across a range of epidemiological
settings to identify the optimal mix of interventions that
is efficacious, cost-effective, and superior to the syn-
dromic management of STIs/RTIs in pregnancy.
Conclusions
There was a high prevalence of curable STIs/RTIs in this
population of pregnant women, a large proportion of
which were not diagnosed and thus untreated. Syn-
dromic management of curable STIS/RTIs is inadequate
in this rural antenatal setting.
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